Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

Table 1 Source overview of clinical inputs

Clinical input	Usual care	Tiotropium	Glycopyrronium
Transition probabilities
Cycles on treatment (year 0–4)	UPLIFT (UC arm)	UPLIFT (TIO arm)	UPLIFT (TIO arm)^a
Cycles off treatment (year 4–>)	UPLIFT (UC arm)	UPLIFT (UC arm)^b	UPLIFT (UC arm)^b
Probabilities of exacerbations
Baseline risks of exacerbations	UPLIFT (UC arm)	UPLIFT (TIO arm)	UPLIFT (TIO arm)
Relative risks	1.00	N/A (probs applied)	SPARK RR TIO/GLY^c

^aSeveral trials have shown comparable efficacy between tiotropium and glycopyrronium in terms of overall lung function (FEV₁)
^bAs there is little persistence in the effect of LAMAs after stopping treatment, transition probabilities were assumed to return to the placebo arm (usual care) probabilities in the cycle after stopping treatment
^cApplied to baseline risks of exacerbations from UPLIFT (TIO arm)

ISSN: 1478-7547